Research Biokin bispecific ADC iza-bren hits goal in lung cancer trial, boosting case for BMS’ global testBy Healthcare Propulsion StaffAugust 18, 20260 Biokin Pharma’s iza-bren, a first-in-class antibody-drug conjugate partnered with Bristol Myers Squibb, has posted another positive phase 3 readout. The…
Research AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failureBy Healthcare Propulsion StaffAugust 17, 20260 AstraZeneca reported positive results from two non-small cell lung cancer trials for Enhertu and an Orpathys-Tagrisso combination, although the dual…
